Key facts
- CytoAgents’s last known valuation is $52.0M (May 2023).
- It has raised $38.6M across 2 recorded rounds; the latest was Early Stage VC ($7.0M) in May 2023.
- Notable investors include National Institutes of Health, Innovation Works, Richard King Mellon Foundation, AlphaLab Health, BlueTree Allied Angels — 15 tracked in total.
- CytoAgents has filed 2 Form Ds with the SEC since 2021, most recently May 2023 ($7.0M sold to 23 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for CytoAgents
Funding rounds
2 roundsAbout CytoAgents
Developer of pharmaceutical drugs designed to treat cytokine release syndrome. The company's drugs develop a broadly accessible treatment for multiple indications of high unmet need, including oncology CAR-T cell therapy, COVID-19, and respiratory epidemics, enabling physicians to effectively treat patients suffering from CRS through a novel approach by calming the natural immune response to a multi-organ disease.
- Sector
- Healthcare
- HQ
- Pittsburgh, PA, United States
- Founded
- 2018
- Employees
- 10
- Website
- cytoagents.com/
- Ownership
- Privately Held (backing)
CytoAgents doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CytoAgents shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CytoAgents in its N-PORT filings yet. We sweep new filings monthly.